Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of CDFF0318 and Champix in Healthy Males
NCT04631874Phase 1Completed
- Sponsor
- CTC Bio
- Start
- Jul 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CDFF0318 in nicotine dependence (2 arms), sponsored by CTC Bio. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Jul 2019; status: completed.
02
Drugs
CDFF0318
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT04631874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631874.